Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences' stock price has experienced significant volatility and decline over the past six months, decreasing by 56.60% and by 92.72% over the past year. Key events include a stock rise on October 6, 2025, following EMA advice, a report of reduced Q2 losses and expenses on August 14, 2025, a rating upgrade to "Buy" on July 15, 2025, and an insider purchase by the CEO on July 2, 2025. The stock price has fluctuated, with a 52-week range between $2.71 and $48.30, and as of November 24, 2025, the share price was $2.90.

As a clinical-stage biopharmaceutical company, Cellectar Biosciences' products are primarily in clinical trials and not yet widely commercialized, so traditional demand seasonality is not directly applicable. The demand for its investigational drugs is driven by clinical trial needs, regulatory milestones, and the prevalence of specific cancer types, rather than seasonal fluctuations.

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments, utilizing its Phospholipid Drug Conjugate (PDC) delivery platform to target cancer cells for improved efficacy and reduced side effects. Its pipeline includes Iopofosine I-131 (CLR 131), currently in clinical trials for Waldenstrom's macroglobulinemia (WM) and other B-cell malignancies, CLR 125 intended to treat micro metastatic disease, CLR 124 designed to detect tumors and metastases, CLR 1502 for intraoperative tumor illumination, CLR 1900 a preclinical chemotherapeutic program, and CLR 12120 Series a PDC-based alpha-emitter radiotherapeutic series.

Cellectar Biosciences, Inc. is headquartered in Florham Park, New Jersey, and focuses on developing and commercializing cancer treatments in the United States. The company plans to submit a Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) for iopofosine I-131, with potential EMA approval and commercial launch across EMA's 30 countries anticipated in 2027.

Cellectar Biosciences' brand reputation is closely tied to its clinical development progress and financial performance. Positive developments, such as the CLOVER-WaM study meeting its primary endpoint and the FDA granting Fast Track Designation for iopofosine in WM, contribute positively to its scientific and clinical standing. Significant stock price declines could reflect investor sentiment and potentially impact overall perception.

Cellectar Biosciences has a mixed ownership structure, with institutional shareholders owning approximately 6.98% to 16.41% of the stock, insiders holding 5.04% to 93.96%, and retail investors owning 0.00% to 60.16%. Major institutional owners include Rosalind Advisors Inc., AIGH Capital Management LLC, and Vanguard Group Inc. The largest individual shareholder is Austin W. Greenhouse David M. Marxe, owning 26.94% of the company.